Dr. Uesaka on Gemcitabine vs S-1 in Pancreatic Cancer

Video

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

Katsuhiko Uesaka, MD, PhD, medical deputy director at Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

In the phase III trial, 378 Japanese patients with resected pancreatic cancer were randomized to receive adjuvant treatment with the chemotherapy S-1 or gemcitabine. The goal of the trial was to prove that S-1 was noninferior to gemcitabine, in this patient population.

At the first interim analysis, the risk of death was 44% lower in the S-1 arm versus the gemcitabine group (HR = 0.56; P <.0001). The 2-year overall survival rate was 70% with S-1 versus 53% with gemcitabine.

Uesaka notes that this data shows that S-1 is significantly noninferior and superior to gemcitabine as an adjuvant treatment for pancreatic cancer.

<<<

View more information on this trial

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,